Shares were up 13%—erasing losses in the year to date—after the company raised its annual guidance for the second time this year, citing strong U.S. demand for its blockbuster drug.
Source link
UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook
Date:
More like thisRelated
Russia pounds Ukraine with missiles and drones, hours after agreeing to peace talks
KYIV, Ukraine -- Russian attacks on Ukraine's capital with...
Child told to keep 'chokehold' secret, bribed with 'squishy toy'
EL PASO, Texas (KTSM) -- A 6-year-old child told...
Zac Brown ‘Duets’ With Dolly Parton on ‘Butterfly’
The country music icon, who died in August, originally...
Aramco CEO Says East-West Pipeline Capacity Could Reach 10 Million Barrels a Day
Saudi Aramco is working to increase the capacity of...